Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$1.31
0.064.80%
At close: -
$1.28
-0.03-2.29%
After Hours: May 12, 6:19 PM EDT
Comments
Loading...
VYNE Therapeutics Analyst Ratings and Price Targets | NASDAQ:VYNE | Benzinga
VYNE Therapeutics Inc has a consensus price target of $7.17 based on the ratings of 3 analysts. The high is $9 issued by Cantor Fitzgerald on May 12, 2023. The low is $4.5 issued by HC Wainwright & Co. on April 25, 2025. The 3 most-recent analyst ratings were released by HC Wainwright & Co. on April 25, 2025, March 6, 2025, and February 19, 2025, respectively. With an average price target of $5.33 between HC Wainwright & Co., there's an implied 316.67% upside for VYNE Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
BTIG
Cantor Fitzgerald
1calculated from analyst ratings
Analyst Ratings for VYNE Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/25/2025 | Buy Now | 251.56% | HC Wainwright & Co. | Joseph Pantginis44% | $5.75 → $4.5 | Maintains | Buy | Get Alert |
| 03/06/2025 | Buy Now | 349.22% | HC Wainwright & Co. | Joseph Pantginis44% | $5.75 → $5.75 | Reiterates | Buy → Buy | Get Alert |
| 02/19/2025 | Buy Now | 349.22% | HC Wainwright & Co. | Joseph Pantginis44% | $5.75 → $5.75 | Reiterates | Buy → Buy | Get Alert |
| 01/14/2025 | Buy Now | 349.22% | HC Wainwright & Co. | Joseph Pantginis44% | $5.75 → $5.75 | Reiterates | Buy → Buy | Get Alert |
| 01/06/2025 | Buy Now | 349.22% | HC Wainwright & Co. | Joseph Pantginis44% | $5.75 → $5.75 | Reiterates | Buy → Buy | Get Alert |
| 12/23/2024 | Buy Now | 349.22% | HC Wainwright & Co. | Joseph Pantginis44% | $5.75 → $5.75 | Reiterates | Buy → Buy | Get Alert |
| 11/18/2024 | Buy Now | 525% | BTIG | Julian Harrison37% | → $8 | Initiates | → Buy | Get Alert |
| 11/08/2024 | Buy Now | 349.22% | HC Wainwright & Co. | Joseph Pantginis44% | $5.75 → $5.75 | Reiterates | Buy → Buy | Get Alert |
| 09/12/2024 | Buy Now | 349.22% | HC Wainwright & Co. | Joseph Pantginis44% | $5.75 → $5.75 | Reiterates | Buy → Buy | Get Alert |
| 08/15/2024 | Buy Now | 349.22% | HC Wainwright & Co. | Joseph Pantginis44% | $5.75 → $5.75 | Reiterates | Buy → Buy | Get Alert |
| 06/14/2024 | Buy Now | 349.22% | HC Wainwright & Co. | Joseph Pantginis44% | $5.75 → $5.75 | Reiterates | Buy → Buy | Get Alert |
| 06/05/2024 | Buy Now | 349.22% | HC Wainwright & Co. | Joseph Pantginis44% | $5.75 → $5.75 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2024 | Buy Now | 349.22% | HC Wainwright & Co. | Joseph Pantginis44% | $5.75 → $5.75 | Reiterates | Buy → Buy | Get Alert |
| 05/06/2024 | Buy Now | 349.22% | HC Wainwright & Co. | Joseph Pantginis44% | $5.75 → $5.75 | Reiterates | Buy → Buy | Get Alert |
| 02/29/2024 | Buy Now | 349.22% | HC Wainwright & Co. | Joseph Pantginis44% | $5.75 → $5.75 | Reiterates | Buy → Buy | Get Alert |
| 10/30/2023 | Buy Now | 349.22% | HC Wainwright & Co. | Joseph Pantginis44% | $28 → $5.75 | Maintains | Buy | Get Alert |
| 08/14/2023 | Buy Now | 2087.5% | HC Wainwright & Co. | Joseph Pantginis44% | $28 → $28 | Reiterates | Buy → Buy | Get Alert |
| 05/12/2023 | Buy Now | 603.13% | Cantor Fitzgerald | Louise Chen53% | $5 → $9 | Maintains | Overweight | Get Alert |
| 05/12/2023 | Buy Now | 2087.5% | HC Wainwright & Co. | Joseph Pantginis44% | → $28 | Reiterates | Buy → Buy | Get Alert |
| 04/19/2023 | Buy Now | 2087.5% | HC Wainwright & Co. | Joseph Pantginis44% | → $28 | Reiterates | → Buy | Get Alert |
| 03/30/2023 | Buy Now | 2087.5% | HC Wainwright & Co. | Joseph Pantginis44% | $1.5 → $28 | Reiterates | → Buy | Get Alert |
| 03/14/2023 | Buy Now | 2087.5% | HC Wainwright & Co. | Joseph Pantginis44% | $1.5 → $28 | Reiterates | → Buy | Get Alert |
| 08/10/2022 | Buy Now | 17.19% | HC Wainwright & Co. | Joseph Pantginis44% | $7 → $1.5 | Maintains | Buy | Get Alert |
FAQ
What is the target price for VYNE Therapeutics (VYNE) stock?
The latest price target for VYNE Therapeutics (NASDAQ:VYNE) was reported by HC Wainwright & Co. on April 25, 2025. The analyst firm set a price target for $4.50 expecting VYNE to rise to within 12 months (a possible 251.56% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for VYNE Therapeutics (VYNE)?
The latest analyst rating for VYNE Therapeutics (NASDAQ:VYNE) was provided by HC Wainwright & Co., and VYNE Therapeutics maintained their buy rating.
When was the last upgrade for VYNE Therapeutics (VYNE)?
There is no last upgrade for VYNE Therapeutics
When was the last downgrade for VYNE Therapeutics (VYNE)?
There is no last downgrade for VYNE Therapeutics.
When is the next analyst rating going to be posted or updated for VYNE Therapeutics (VYNE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of VYNE Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for VYNE Therapeutics was filed on April 25, 2025 so you should expect the next rating to be made available sometime around April 25, 2026.
Is the Analyst Rating VYNE Therapeutics (VYNE) correct?
While ratings are subjective and will change, the latest VYNE Therapeutics (VYNE) rating was a maintained with a price target of $5.75 to $4.50. The current price VYNE Therapeutics (VYNE) is trading at is $1.28, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
